-
Innovation Ranking
Innovation Ranking – JL Mag Rare-Earth Co Ltd
Jlmag Rare-Earth Co Ltd (Jlmag) is a manufacturer of rare earth permanent magnetic materials. The company engaged in the research and development, production, and sale of permanent magnetic materials. It provides various grades of NdFeB magnets. Jlmag also provides R&D equipment that comprises MPS Permagraph, salt spray test chamber, vacuum melting furnace, wire cutting machines and flux meters. The company’s products are used in wind power, new energy vehicles, inverter air conditioners, energy-saving elevators and other industrial energy-saving motors. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – New Generation, Targeting Rare And Refractory Mutations Of EGFR in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - New Generation, Targeting Rare And Refractory Mutations Of EGFR in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. New...
-
Thematic Analysis
Rare Disease ​Pipeline Analysis ​Landscape, 2023
This report investigates the Rare Disease ​Pipeline Analysis ​Landscape in 2023 in the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize these trends within your sector.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INZ-701 in Rickets
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INZ-701 in Rickets report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INZ-701 in Rickets Drug Details: INZ-701 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SAN-711 in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SAN-711 in Epilepsy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SAN-711 in Epilepsy Drug Details: SAN-711 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INZ-701 in Arterial Calcification
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INZ-701 in Arterial Calcification report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INZ-701 in Arterial Calcification Drug Details: INZ-701 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INZ-701 in Calciphylaxis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INZ-701 in Calciphylaxis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INZ-701 in Calciphylaxis Drug Details: INZ-701 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INZ-701 in Pseudoxanthoma Elasticum (PXE or Gronblad Strandberg Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INZ-701 in Pseudoxanthoma Elasticum (PXE or Gronblad Strandberg Syndrome) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INZ-701 in Pseudoxanthoma Elasticum (PXE or...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INZ-701 in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INZ-701 in End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INZ-701 in End-Stage Kidney Disease...
-
Product Insights
NewMuscarinic Acetylcholine Receptor M4 – Drugs In Development, 2024
The Muscarinic Acetylcholine Receptor M4 pipeline drugs market research report outlays comprehensive information on the Muscarinic Acetylcholine Receptor M4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Genetic Disorders, Undisclosed, and Cardiovascular which include indications of Schizophrenia, Alzheimer's Disease, Fragile X Syndrome, Tuberous Sclerosis, Unspecified Rare Disease, and Systolic Hypertension. It also reviews key...